Targeting purine biosynthesis to radiosensitize glioblastoma
靶向嘌呤生物合成使胶质母细胞瘤放射增敏
基本信息
- 批准号:10229208
- 负责人:
- 金额:$ 6.82万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-05-01 至 2024-02-29
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdenineAdenosineAllyAmino AcidsAnabolismBrain NeoplasmsCarbonCell Culture TechniquesCellsChemotherapy and/or radiationClinical TrialsCommunicationDNA DamageDNA-dependent protein kinaseDataEventExhibitsFDA approvedFRAP1 geneFutureGlioblastomaGlucoseGuanineGuanosineHypoxanthinesLeadLeftLinkMalignant NeoplasmsMeasurementMediatingMediator of activation proteinMetabolicMetabolic PathwayMetabolismMethodologyMethodsMichiganModelingMonosaccharidesMusNational Research Service AwardsNatureOperative Surgical ProceduresOrangesPathway interactionsPatient-Focused OutcomesPatientsPharmacologyPrimary Brain NeoplasmsProto-Oncogene Proteins c-aktPublishingPurine AntagonistPurinesRadiationRadiation Dose UnitRadiation Induced DNA DamageRadiation therapyResearchResearch ProposalsResistanceSignal PathwaySignal TransductionSupplementationTechniquesTestingUnited States National Institutes of HealthUniversitiesWorkadenylatebaseexpectationexperimental studygenetic approachguanylateimprovedin vitro Modelin vivoin vivo Modelinhibitor/antagonistmetabolic phenotypemetabolomicsmycophenolate mofetilnovelnucleobasepatient derived xenograft modelpurine metabolismradiation effectradiation resistanceradiation responseradioresistantrandomized trialrepairedresponsestable isotopesugartargeted treatmenttherapy resistanttumor
项目摘要
Project Summary/Abstract
Glioblastoma (GBM) is the most common aggressive primary brain tumor and is uniformly fatal with a median
survival of around 1.5 years. Like surgery and chemotherapy, radiation (RT) is a critical treatment for nearly
every patient with GBM and has repeatedly improved patient survival in multiple randomized trials. Still, 80% of
GBMs recur within the high dose RT field. Thus, there is a critical need to develop strategies to overcome GBM
RT resistance to further improve patient outcomes.
GBM cells exhibit profound cancer-specific metabolic abnormalities, including elevated purine synthesis, to fuel
proliferation, invasion and survival. Using mice bearing intracranial orthotopic patient-derived brain tumors, my
research has established that the metabolic phenotype of elevated purine synthesis also mediates resistance to
RT in GBM by promoting the repair of RT-induced DNA damage. This purine-mediated RT resistance can be
overcome by treatment with mycophenolate mofetil (MMF), an FDA-approved and CNS-penetrant inhibitor of
purine biosynthesis.
In this research proposal I will determine how the RT response and purine synthesis regulate one another in
GBM. By employing a variety of cutting-edge metabolomic techniques and patient-derived GBM models, I will 1)
define the biosynthetic pathway GBMs use to generate purines, and 2) determine the RT response mechanism
by which GBMs increase purine levels to resist RT-induced DNA damage.
Findings from the experiments proposed here will expand our understanding of how tumors modulate
metabolism to promote therapeutic resistance, inform how to combine metabolic inhibitors with standard
therapies, and lay the mechanistic groundwork for clinical trials at the University of Michigan that targeting purine
biosynthesis to augment RT in GBM patients.
项目摘要/摘要
胶质母细胞瘤(GBM)是最常见的侵袭性原发脑肿瘤,平均致死率为
存活时间约为1.5年。与手术和化疗一样,放射治疗(RT)是近
在多个随机试验中,每个患有GBM的患者都反复提高了患者的存活率。尽管如此,80%的
大剂量RT野内可见GBMS复发。因此,迫切需要制定战略来克服大流行病。
RT抵抗,以进一步改善患者的预后。
GBM细胞表现出严重的癌症特异性代谢异常,包括嘌呤合成增加,以补充燃料
扩散、侵袭和存活。利用携带颅内原位患者脑肿瘤的小鼠,我的
研究已经证实,嘌呤合成增加的代谢表型也介导了对
RT通过促进RT诱导的DNA损伤修复而在GBM中发挥作用。这种嘌呤介导的RT耐药可以是
可通过霉酚酸酯(MMF)治疗,MMF是FDA批准的一种中枢神经系统穿透抑制药
嘌呤生物合成。
在这个研究方案中,我将确定RT反应和嘌呤合成是如何在
GBM。通过使用各种尖端代谢组学技术和患者衍生的GBM模型,我将1)
定义GBM用来产生嘌呤的生物合成途径,以及2)确定RT反应机制
通过这种方式,GBM增加了嘌呤水平,以抵抗RT诱导的DNA损伤。
这里提出的实验结果将扩大我们对肿瘤如何调节的理解
代谢促进治疗耐药,告知如何将代谢抑制剂与标准药物结合
疗法,并为密歇根大学针对嘌呤的临床试验奠定了机械基础
生物合成以增强GBM患者的RT。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew Joseph Scott其他文献
Andrew Joseph Scott的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew Joseph Scott', 18)}}的其他基金
Targeting purine biosynthesis to radiosensitize glioblastoma
靶向嘌呤生物合成使胶质母细胞瘤放射增敏
- 批准号:
10376755 - 财政年份:2021
- 资助金额:
$ 6.82万 - 项目类别:
Targeting purine biosynthesis to radiosensitize glioblastoma
靶向嘌呤生物合成使胶质母细胞瘤放射增敏
- 批准号:
10598506 - 财政年份:2021
- 资助金额:
$ 6.82万 - 项目类别:
相似海外基金
The Role of Adenine Nucleotide Translocase in Mitochondrial Dysfunction Associated Senescence in Chronic Obstructive Pulmonary Disease (COPD)
腺嘌呤核苷酸转位酶在慢性阻塞性肺病(COPD)线粒体功能相关衰老中的作用
- 批准号:
10633608 - 财政年份:2023
- 资助金额:
$ 6.82万 - 项目类别:
Pathways of Succinate Accumulation and Adenine Nucleotide Depletion in Cardiac Ischemia
心脏缺血中琥珀酸积累和腺嘌呤核苷酸消耗的途径
- 批准号:
10534031 - 财政年份:2022
- 资助金额:
$ 6.82万 - 项目类别:
Pathways of Succinate Accumulation and Adenine Nucleotide Depletion in Cardiac Ischemia
心脏缺血中琥珀酸积累和腺嘌呤核苷酸消耗的途径
- 批准号:
10794933 - 财政年份:2022
- 资助金额:
$ 6.82万 - 项目类别:
Development of nobel assay methods for miRNA and adenine methyltransferase using FRET
使用 FRET 开发 miRNA 和腺嘌呤甲基转移酶的诺贝尔检测方法
- 批准号:
21K05120 - 财政年份:2021
- 资助金额:
$ 6.82万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Critical assessment of DNA adenine methylation in brain cells from healthy aging and Alzheimer's disease
健康老龄化和阿尔茨海默病脑细胞 DNA 腺嘌呤甲基化的批判性评估
- 批准号:
10365337 - 财政年份:2021
- 资助金额:
$ 6.82万 - 项目类别:
DNA Methylation at N6-Adenine in Placental Trophoblast Development
胎盘滋养层发育中 N6-腺嘌呤 DNA 甲基化
- 批准号:
10033546 - 财政年份:2020
- 资助金额:
$ 6.82万 - 项目类别:
DNA Methylation at N6-Adenine in Placental Trophoblast Development
胎盘滋养层发育中 N6-腺嘌呤 DNA 甲基化
- 批准号:
10613902 - 财政年份:2020
- 资助金额:
$ 6.82万 - 项目类别:
DNA Methylation at N6-Adenine in Placental Trophoblast Development
胎盘滋养层发育中 N6-腺嘌呤 DNA 甲基化
- 批准号:
10396102 - 财政年份:2020
- 资助金额:
$ 6.82万 - 项目类别:
DNA Methylation at N6-Adenine in Placental Trophoblast Development
胎盘滋养层发育中 N6-腺嘌呤 DNA 甲基化
- 批准号:
10226235 - 财政年份:2020
- 资助金额:
$ 6.82万 - 项目类别:
DNA Methylation at N6-Adenine in Placental Trophoblast Development
胎盘滋养层发育中 N6-腺嘌呤 DNA 甲基化
- 批准号:
10705982 - 财政年份:2020
- 资助金额:
$ 6.82万 - 项目类别: